Aspirin for the primary prevention of cardiovascular events

Drugs of Today

Volumn 42, Issue 7, 2006, Pages 467-479

  Colwell, John A ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CORTICOSTEROID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESOMEPRAZOLE; PLACEBO; PROSTAGLANDIN SYNTHASE; PROTON PUMP INHIBITOR; THIAZIDE DIURETIC AGENT; THROMBOXANE; WARFARIN;

BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIABETIC RETINOPATHY; DIGESTIVE SYSTEM ULCER; DRUG ADSORPTION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MIXTURE; DRUG UTILIZATION; ENTERIC COATED TABLET; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; STROKE; SYSTEMATIC REVIEW; THROMBOCYTE AGGREGATION; THROMBOSIS;

ASPIRIN; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; META-ANALYSIS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES;

EID: 33747126830     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2006.42.7.1009900     Document Type: Review

References (36)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324: 71-86.
2. Patrono, C., Garcia Rodriguez, L.A., Landolfi, R., Baigent, C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005, 353: 2373-83.
3. Karha, J., Rajagopal, V., Kottke-Marchant, K., Bhatt, D.L. Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers. Am Heart J 2006, 151: 976.e7-11.
4. Stampfer, M.J., Jakubowski, J.A., Deykin, D., Schafer, A.I., Willett, W.C., Hennekens, C.H. Effect of alternate-day regular and enteric-coated aspirin on platelet aggregation, bleeding time, and thromboxane A2 levels in bleeding-time blood. Am J Med 1986, 81: 400-4.
5. DiMinno, G., Silver, M.J., Cerbone, A.M., Murphy, S. Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 1986, 68: 886-91.
6. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989, 321: 129-35.
7. Peto, R., Gray, R., Collins, R. Randomised trial of prophylactic daily aspirin in British male doctors. British Medical Journal 1988, 296: 313-6.
8. The Medical Research Council's General Research Framework. Thrombosis prevention trial: Randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998, 351: 233-41.
9. Hansson, L., Zanchetti, A., Carruthers, S.G. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351: 1755-62.
10. Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomized trial in general practice. Lancet, 2001, 357: 89-94.
11. Ridker, P.M., Cook, N.R., Lee, I.M. et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005, 352: 1293-304.
12. Hennekens, C.H., Hollar, D., Baigent, C. Sex-related differences in response to aspirin in cardiovascular disease: An untested hypothesis. Nature Clinical Practice 2006, 3: 4-5.
13. Sanmuganathan, P.S., Ghahramani, P., Jackson, P.R., Wallis, E.J., Ramsay, L.E. Aspirin for primary prevention of coronary heart disease: Safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001, 85: 265-71.
14. Eidelman, R.S., Hebert, P.R., Weisman, S.M., Hennekens, C.H. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003, 163: 2006-10.
15. Berger, J.S., Roncaglioni, M.C., Avanzini, F., Pangrazzi, I., Tognoni, G., Brown, D.L. Aspirin for the primary prevention of cardiovascular events in women and men: A sex-specific meta-analysis of randomized controlled trials. JAMA 2006, 295: 306-13.
16. Pignone, M., Earnshaw, S., Tice, U.A., Pletcher, M.J. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: A cost-utility analysis. Ann Intern Med 2006, 144: 326-36.
17. Nelson, M.R., Liew, D.L., Bertham, M., Vos, T. Epidemiological modelling of routine use of low-dose aspirin for the primary prevention of coronary heart disease and stroke in those aged ≥70. BMJ 2005, 330: 1306.
18. Nelson, M.R., Reid, C.M., Beilin, L.J. et al.; Aspirin in Reducing Events in the Elderly (ASPREE) Study Group. Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly. Aspirin in Reducing Events in the Elderly (ASPREE). Drugs Aging 2003, 20: 897-903.
19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285: 2486-97.
20. Haffner, S.M., Lehto, S., Ronnemaa, T., Pyorala, K., Laakso, M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339: 229-34.
21. Howard, B.V., Best, L.G., Galloway, J.M. et al. Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care 2006, 29: 391-7.
22. Rolka, D.B., Fagot-Campagna, A., Narayan, K.M. Aspirin use among adults with diabetes: Estimates from the Third National Health and Nutrition Examination Survey. Diabetes Care 2001, 24: 197-201.
23. Colwell, J.A. Aspirin therapy in diabetes. Diabetes 1997, 20: 1767-71.
24. ETDRS Investigators. Aspirin effects on mortality and morbidity in prints with diabetes mellitus. JAMA 1992, 268: 1292-300.
25. Sacco, M., Pellegrini, F., Rancaglioni, M.C., Avanzini, F., Tognoni, G., Nicolucci, A.; PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients. Diabetes Care 2003, 26: 3264-72.
26. ASCEND trial Web site (http://www.ctsu.ox.ac. uk/ascend/index.htm) accessed June 1, 2006.
27. U.S. National Institutes of Health Web site (http://www.clinicaltrials. gov). Japanese Primary Prevention of Astherosclerosis with Aspirin for Diabetes (JPAD) trial description accessed June 1, 2006.
28. Garcia Rodriguez, L.A., Hernandez-Diaz, S., Abojo, F. Association between aspirin and upper-gastrointestinal complications: Systematic review of epidemiologic studies. Br J Clin Pharmacol 2001, 52: 563-71.
29. Cryer, M.D. Reducing the risks of gastrointestinal bleeding with antiplatelet therapies. N Engl J Med 2005, 352: 287-9.
30. Chan, F.K., Ching, J.Y., Hung, L.C. et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005, 352: 238-44.
31. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2004, 27: 161-72.
32. AHA Scientific Statement. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Circulation 2002, 106: 388-91.
33. U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: Summary of the evidence. Ann Intern Med 2002, 136: 161-72.
34. Patrono, C., Bachmann, F., Baigent, C. et al. Expert consensus document on the use of anti-platelet agents. The task force on the use of anti-platelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur Heart J 2004, 25: 166-81.
35. Wilson, P.W., D'Agostino, R.B., Levy, D., Belanger, A.M., Silbershatz, H., Kannel, W.B. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97: 1837-47.
36. Stevens, R.J., Kothari, V., Adler, A.I., Stratton, I.M.; United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: A model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clinical Science 2001, 101:671-9.